Ageing does not weaken the body through a single biological switch. Muscle fibres gradually lose their ability to grow and repair, energy metabolism becomes less efficient, and persistent oxidative stress damages proteins, membranes and cellular signalling systems. A new study published in Experimental & Molecular Medicine now reports that meloxicam, a widely used anti-inflammatory drug, may counter several of these changes by restoring the activity of a molecule called Cdon and moderating oxidative stress.
The findings place an established medicine in an unexpected scientific context. Meloxicam is best known as a non-steroidal anti-inflammatory drug, or NSAID, prescribed to reduce pain and inflammation in conditions such as arthritis. Its primary pharmacological action involves inhibiting cyclooxygenase enzymes, which participate in the production of prostaglandins—lipid signalling molecules that help drive inflammation, pain and fever. The new research suggests that its effects in ageing muscle may extend beyond conventional inflammation control, involving molecular pathways associated with tissue maintenance and metabolic health.
The study by JH Bae, HK So, Y Jeong and colleagues focuses on Cdon, a cell-surface protein involved in communication between neighbouring cells. Cdon belongs to the immunoglobulin superfamily of adhesion molecules and helps cells interpret their physical and biochemical environment. In skeletal muscle, such communication is important for the behaviour of muscle stem cells, also known as satellite cells. These cells remain largely inactive in healthy adult tissue but can be activated after injury or physiological stress, multiplying and contributing to the repair and formation of muscle fibres.
With advancing age, the regenerative capacity of skeletal muscle declines. Satellite cells may become less responsive, the surrounding tissue can become more inflammatory, and the balance between damage and repair shifts in the wrong direction. The study identifies reduced Cdon activity as part of this age-associated deterioration and reports that meloxicam treatment restored Cdon-related signalling. This restoration was associated with protection against muscle decline, suggesting that the drug may influence the cellular environment in which regeneration takes place rather than simply suppressing symptoms such as pain.
The researchers also connect the reported benefits to oxidative stress. Cells continuously generate reactive oxygen species as a consequence of mitochondrial energy production and other metabolic reactions. At controlled levels, these molecules function as signalling agents. When their production exceeds the capacity of antioxidant systems to neutralise them, however, they can oxidise proteins, lipids and nucleic acids. Ageing tissues are particularly vulnerable because mitochondrial performance, antioxidant defences and cellular repair systems can all deteriorate over time.
Muscle is an energy-intensive tissue, and its function depends on a stable relationship between energy production, protein turnover and redox balance. Excessive oxidative stress can interfere with contractile proteins, impair mitochondrial membranes and disrupt signalling pathways that regulate muscle growth. It can also promote inflammatory responses, creating a cycle in which inflammation generates further oxidative damage and oxidative damage sustains inflammation. According to the study, meloxicam helped moderate this damaging environment while restoring Cdon, providing a possible explanation for its protective effects on ageing muscle.
The implications extend beyond muscle size alone. Age-related muscle decline is closely linked to metabolic dysfunction, reduced physical resilience and loss of independence. Skeletal muscle acts as a major site of glucose disposal and energy use, meaning that deterioration in muscle quality can affect whole-body metabolism. The researchers report that meloxicam protected against both muscular and metabolic decline, indicating that the Cdon and oxidative-stress pathways may connect tissue regeneration with broader changes in how the ageing body handles energy.
That connection is scientifically important because many approaches to ageing-related muscle loss target only one component of the problem. Exercise can stimulate muscle protein synthesis and improve mitochondrial function, while nutritional strategies can support energy and amino-acid availability. Anti-inflammatory treatments may reduce damaging immune activity, but long-term suppression of inflammation can also carry risks because inflammatory signalling is necessary for normal repair and immune defence. A treatment that adjusts oxidative stress and restores regenerative signalling could therefore be more relevant than one that simply eliminates inflammation.
Still, the findings do not mean that meloxicam should be taken as an anti-ageing medicine. NSAIDs can cause serious adverse effects, especially when used repeatedly or at high doses. These may include gastrointestinal bleeding, kidney injury, fluid retention and increased cardiovascular risk in susceptible individuals. The balance between benefit and harm depends on dose, treatment duration, age, underlying disease and interactions with other medicines. Before the reported mechanism could influence clinical practice, it would need to be tested rigorously in appropriately designed human studies that measure muscle strength, physical performance, metabolic health and long-term safety.
The study nevertheless offers a striking example of how ageing research can uncover new biological roles for familiar drugs. By placing Cdon restoration and oxidative-stress modulation at the centre of meloxicam’s reported effects, the work proposes a mechanistic framework for understanding how inflammation, cell communication and metabolism converge in ageing muscle. It also raises a broader possibility: medicines developed for one biological purpose may contain underexplored activities that become valuable when viewed through the lens of tissue regeneration. For now, the results represent a promising preclinical direction rather than a ready-made therapy, but they add momentum to the search for interventions capable of preserving muscle and metabolic function across the lifespan.
Subject of Research: Meloxicam’s protective effects against age-related muscle and metabolic decline through Cdon restoration and oxidative-stress modulation.
Article Title: Meloxicam protects against muscle and metabolic decline in ageing through Cdon restoration and oxidative stress modulation.
Article References: Bae, JH., So, HK., Jeong, Y. et al. “Meloxicam protects against muscle and metabolic decline in ageing through Cdon restoration and oxidative stress modulation.” Experimental & Molecular Medicine (2026). https://doi.org/10.1038/s12276-026-01804-1
Image Credits: AI Generated
DOI: 10.1038/s12276-026-01804-1
Keywords: Meloxicam, ageing, skeletal muscle, muscle regeneration, Cdon, oxidative stress, metabolism, inflammation, anti-inflammatory drugs, cellular ageing
Tags: aging muscle protectionCdon protein restoration in ageingcyclooxygenase enzyme inhibition beyond pain reliefinflammation modulation in ageingmeloxicam anti-inflammatory effectsmetabolic health and muscle functionmolecular pathways in muscle ageingmuscle fibre maintenance in elderlymuscle repair and regeneration mechanismsNSAIDs and muscle healthoxidative damage prevention in tissuesoxidative stress reduction in muscle
